Met-HBV: Diagnosis and Management with MASLD in Patients with Chronic HBV Infection

Create Account

Availability

Registration Required

https://aasld.zoom.us/j/83906652413

Jan 29, 2026 12:00 PM - 1:00 PM ET

Cost

$0.00

Credit Offered

1 AMA PRA Category 1 Credit

Description
Learning Objectives
Accreditation Information
Faculty and Disclosures

This activity is presented by the HBV SIG Steering Committee and is intended to address the intersection of MASLD and metabolic syndrome in patients with chronic HBV. This, which represents an increasingly common issue encountered in clinical practice. This activity aims to summarize current evidence regarding this relationship and its implications for clinical practice and identify best practices for diagnosis and management. This webinar will address several topics identified as priorities: identification and treatment of MASLD/MASH and comorbid metabolic conditions (DM, obesity), use of noninvasive tests (NITs) in risk stratification, management of chronic hepatitis B, and practice management for integration of care/multidisciplinary care.

Upon completion of this activity, participants should be able to:

• Define the epidemiology of MASLD and metabolic syndrome in patients with chronic HBV infection
• Describe how the presence of MASLD and/or metabolic syndrome significantly influence HBV virology, pathogenesis, natural history/clinical course, clinical outcome, and virologic response to antiviral therapy
• Identify appropriate diagnostic tests for MASLD and/or metabolic syndrome in patients with chronic HBV infection
• Recognize non-invasive tests (NITs) and/or liver biopsy be used to perform risk stratification and fibrosis staging in patients with both MASLD and chronic HBV
• Describe evidence-based management strategies for the management of MASLD and metabolic syndrome in patients with chronic HBV infection

The American Association for the Study of Liver Diseases is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association for the Study of Liver Diseases designates this blended (live and other) activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Release Date: January 29, 2026
Expiration Date: January 29, 2027

This online educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence for Accredited Continuing Education by members of the AASLD Transplant Hepatology Board Review Course faculty, the AASLD Maintenance of Certification Committee and the AASLD Governing Board. As an accredited provider, AASLD must collect information from all planners, faculty and others in the planning and control of continuing medical education (CME) activities to disclose all of their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the education.

The American Association for the Study of Liver Diseases (AASLD) has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. Conflicts, if any, are resolved through one or more processes. All relevant conflicts pertaining to this activity have been mitigated.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Joseph Lim, MD

Swathi Krishnan, MD

Jiyoon Park, MD